Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Efficacy of Covid-19 Vaccination in Cystic Fibrosis Patients: A Systematic Review Publisher Pubmed



Shahrebabak AG1 ; Rezaei M2 ; Shahpar A3 ; Nezhad NZ4 ; Sarasyabi MS5 ; Nakhaie M3, 6 ; Shahrebabak MG7 ; Bahri RA8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pediatric ،Afzalipour Hospital, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
  2. 2. Research Center for Hydatid Disease in Iran, Kerman University of Medical Sciences, Kerman, Iran
  3. 3. Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman, Iran
  4. 4. Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
  5. 5. Medical Informatics Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
  6. 6. Clinical Research Development Unit, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
  7. 7. Department of Pediatrics, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
  8. 8. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: BMC Infectious Diseases Published:2025


Abstract

This systematic review evaluates the efficacy and safety of COVID-19 vaccines in individuals with cystic fibrosis (CF). A systematic search of major databases conducted between December 2019 and January 2024 identified eight cohort studies comprising 1,361 CF patients. Studies without subgroup analyses specific to CF patients were excluded, which may have limited the generalizability of findings, particularly for CF lung transplant recipients. COVID-19 vaccines generally induced robust serological responses following the second and third doses, although reduced antibody levels were observed in lung transplant recipients. Factors influencing humoral response included prior SARS-CoV-2 infection, age, inhaled corticosteroid use, and immunosuppressive therapy. Vaccination-related adverse events were predominantly mild. Although breakthrough infections were reported, severe COVID-19 outcomes were infrequent among vaccinated CF patients. The evidence supports the immunogenicity and safety of COVID-19 vaccines in the CF patients. However, individualized vaccination strategies may be necessary for CF lung transplant recipients and those on immunosuppressive therapies. Further research is essential to optimize vaccination strategies and to identify risk factors associated with breakthrough infections in this high-risk population. © The Author(s) 2025.
Related Docs
Experts (# of related papers)